Author (year),Country/countries,Setting,Population,Compared strategies,Included treatment,Type of economic evaluation,Model type,Perspective,Clinical outcomes,Time horizon,Discount rate,Inclusion of stochasticity,Inclusion of AMR,ICER,Currency (year),Reporting of uncertainty,Main findings,Cost-effectiveness verdict,CHEERS score,groupname,row
Abimbola (2012),Resource-limited countries in sub-Saharan Africa,Primary care,A group of patients eligible for antiretroviral therapy based on the presence of clinical illness and/or a CD4 cell count of <200 cells/microliter.,"Current practice (symptom screening, sputum smear microscopy, and chest radiography); culture as recommended by WHO guidelines (2007); the WHO algorithm as updated in 2011 and is based on the Xpert MTB/RIF test.",Non-specified TB therapy,CEA,Decision tree,Health system perspective,Synthesis-based estimates,182 days,"NA",Yes,No,"culture: $60,430/death averted; Xpert: dominated",US dollars (2010),"Tornado diagram of DSA, CEAC","A diagnostic approach that includes culture was most effective at averting early deaths, but it was not the least costly approach compared with other algorithms considered. The algorithm with Xpert cost less and was more effective in reducing early mortality compared with the current practice.",Cost-effective,16,decision tree model,1
Ang (2015),Singapore,Hospital,Patients visiting an eye centre with signs suggestive of TB uveitis,TST only; Interferon-gamma release assay (IGRA) following a positive TST;  IGRA only; TST and IGRA simultaneously,Non-specified TB therapy,CEA,Decision tree,Not specified,Single-study based estimates,30 years,economic: NA; health: 3%,Yes,No,TSt: $3611/QALY; IGRA: dominated; TST and IGRA: 11506/QALY (using TST followed by IGRA as reference),Singapore dollars (2010),"Table of DSA, Tornado diagram of DSA, Sensitivity analysis graph (with one parameter varied), CEAC","In the context of our study population, while recognising the difficulties of diagnosing TB uveitis, our results suggest that the dual-test strategy of performing TST and IGRA simultaneously appears to be the most cost-effective strategy relative to the other strategies.",Cost-effective,14,decision tree model,2
Balk (2001),"NA",Primary care,"Patients with suspected, uncomplicated, community-acquired, acute bacterial sinusitis who had had symptoms for less than 4 weeks and who had not had recurrent sinusitis",No patients given antibiotic treatment; all patients given empirical amoxicillin treatment; patients given amoxicillin based on the results of a set of clinical criteria; patients given amoxicillin based on the results of sinus radiography (plain film x-ray),"10-day course of amoxicillin, 250 mg 3 times a day.",CEA,Markov (compartimental) model,Societal perspective,"QALYs, Days free from disease",14 days,"NA",No,Yes,34.0 costs/symptom free day (in a mild scenario),US dollars (year NA),"Deterministic sensitivity analysis (DSA), Table of DSA, Sensitivity analysis graph (with one parameter varied)",The best strategy for diagnosing and treating acute sinusitis depends in part on the prevalence of the bacterial sinusitis (or the likelihood that a given patient actually has the disease),"Cost-saving, Cost-effective",15,markov model,3
Behnamfar (2020),Iran,Hospital,All the hospitalized patients between the years 2011 and 2015,"Treatment for all; no treatment; treatment based on the rapid test for a streptococcal antigen; treatment based on the culture test result; treatment based on RTA plus culture; treatment based on the RTA result, and in the case of a negative result, culturing.",Penicillin,CEA,Decision tree,Healthcare payer's perspective,Synthesis-based estimates,"NA","NA",Yes,No,RTA + culture: 0.007564; RTA: 0.048541; Culture: 0.049706 (unit: costs /quality-adjusted life day),Not reported,Tornado diagram of DSA,The most effective mean observed quality‑adjusted life days was the simultaneous diagnostic treatment of RTA and culture; the highest amount of saving (monetary cost) was detected in RTA before treatment.,Cost-effective,14,decision tree model,4
Bertran (2000),Spain,"Primary care, Hospital","Patients with CAP, less than 65 years old, without hospital admission criteria; Patients with AECB due to respiratory infection.",Simple chest x-ray and a blood count; empirical antibiotics,"Macrolides (erythromycin, clarithromycin, azithromycin, roxithromycin); Fluoroquinolones (ciprofloxacin, ofloxacin); Cephalosporins (cefuroxime, ceftriaxone); Betalactam (penicillin, amoxicillin, amoxicillin clavulanic acid).",CEA,Decision tree,Healthcare centre's perspective,Clinical effectiveness of the first antibiotic option,from the moment the treatment started in primary care to the final healing or clinical failure after a third antibiotic option prescribed in hospital administration,"NA",No,No,"Patients with community-acquired pneumonia (CAP): Betalactam antibiotic treatment is the most cost-effective strategy. Hospitalization, directly related to the success rate of the first empirical antibiotic treatment, is the main driver of the final average cost per patient, rating from 50% to 70% of total cost. Acquisition costs of the first empirical antibiotic treatment represents just a small fraction of the total costs (between 2% and 13%)",Spanish peseta (1998),Deterministic sensitivity analysis (DSA),The model indicates that acquisition costs of the initial empirical antibiotic represent a small fraction of total treatment costs in patients with lower respiratory tract infections acquired in the community,Cost-effective,9,decision tree model,5
Bogdanova (2019),Russian federation,A centre dedicated to the diagnosis and treatment of TB,All the patients diagnosed with MDR-TB,LPA-based diagnostic algorithm (smear positive (SSm+) and for smear negative(SSm-) culture confirmed TB patients by Bactec MGIT or LJ; conventional culture-based algorithm (LJ–for SSm- and SSm+ patients and BacTAlert–for SSm+patients).,NA,CMA,Clinical trial (PROVE-IT Russia),"Societal perspective, Healthcare system perspective",Single-study based estimates,TB treatment duration,"NA",No,Yes,SSm+ LPA-based diagnostics reducuded the costs by 4.5 compared to LJ and by 2.5 times compared to BacTAlert liquid culture,US dollars (2014),Deterministic sensitivity analysis (DSA),TB diagnostic algorithms incorporating LPA method proved to be both more clinically effective and less expensive due to reduction in the number of hospital days to the correct MDR-TB diagnosis and treatment initiation,Cost-saving,15,trial-based analysis,6
Böhmer (2002),Germany,Hospital,Patients hospitalized with community-acquired pneumonia in the internal medicin department,"Current practice; Inquaro, a computer system to aid in diagnosing community-acquired pneumonia patients","Levofloxacin, clarithromycin, ampicillin/sulbactam; ceftriaxon; erythomycin; ampicillin; cefazolin; doxycyclin","CA, CEA",Differences are calculated using T tests,Healthcare centre’s perspective,"Days with symptoms, days with antibiotics, hospital length of stay, application time",Hospital addmission,"NA",No,No,"No incremental cost-effectiveness outcomes reported, only individual costs (microbiology: -11.77; imaging procedures: 8.32; antibiotic costs: -114.04; application costs: -100.41) and individual effects (application time (h): -5.4; days with symptoms: -3.5; days with antibiotics: -3; hospital length-of-stay (days): -3)","NA",Deterministic sensitivity analysis (DSA),"Improvements were found for the patients (fewer infusions, faster symptom resolution and a shorted length-of-stay)",Cost-saving,11,trial-based analysis,7
Bonnet (2010),Kenya,Primary care/urban health clinic,TB-suspected patients (cough of at least 2 weeks),Bleach smear (B) and direct smear (D) (under microscope) in various combinations and orders: D1+D2; B1; B1+B2; D1+B1; B1+D2; D1+B2; D1+B1+D2; D1+D2+B2; D1+B1+B2; B1+D2+B2,Not specified,CEA,Decision tree,Health service provider's perspective,Single-study based estimates,"NA","NA",No,No,"B1+B2: €50; D1+B1: €276; : €71; D1+B1+D2, D1+B2, B1+D2, D1+D2+B2, D1+B1+B2, B1+D2+B2: dominated, measure of effectiveness: costs / proportion of smear-positive patients detected among the total number of PTB suspects (using D1+D2 and B1 as references)",Euros (2006),Table of DSA,"Considering all potential combinations of direct smear and smear after overnight NaOCl sedimentation, the approaches based on the single examination of the first concentrated specimen or based on the examination of two concentrated specimens were the most cost-effective: B1 due to its low cost, and B1+B2 dueto its effectiveness and low ICER compared to B1.",Cost-effective,14,decision tree model,8
Cals (2011),The Netherlands,Primary care,"Eligible patients were aged 18 years or older, consulting with their GP with a new episode of acute cough of up to 28 days and caused by an lower respiratory tract infections (LRTIs) in the GPs view",GPs managed patients in the usual care group with the availability of the Dutch College of GPs guidelines for acute cough: GP use of CRP; GP communication skills training; GP use of CRP and GP communication skills training,NA,CEA,Decision tree,Healthcare payer's perspective,Antibiotic prescriptions saved,28 days,"NA",No,No,The ICER of GP use of CRP versus usual care was €5.79 and for GP use of both CRP and Communication versus usual care €4.15. Communication was superior to usual care costs or savings /antibiotic prescription saved,Euros (Unclear. 2010),Probabilistic sensitivity analysis (PSA),"The interventions are cost-effective in any combination (yielding NMB at no willingness-to pay), taking into account GPs’ preferences where at least 15% of GPs chose to implementthe communication skills training.",Cost-effective,15,decision tree model,9
Cowan (2017),United States,Hospital,Inpatients placed in airborne infection isolation for presumptive pulmonary TB.,1 Xpert on an unconcentrated sputum sample; 1 Xpert on a concentrated sample; 2 Xperts on concentrated sputum samples; 2 smears; and 3 smears,Non-specified TB therapy,CEA,Decision tree,Healthcare centre's perspective,Single-study based estimates,"NA","NA",Yes,No,"XPERT 2 concentrated: $2826682/accurately diagnosed case; 2 smears: $-320893/accurately diagnosed case; 3 smears: $-363987/accurately diagnosed case (reference 1 Xpert concentrated and unconcentrated, which are expected to have equal performance)",US dollars (unknown year),"Tornado diagram of DSA, Two-way sensitivity analysis graph, Probabilistic sensitivity analysis (PSA), CE plane, CEAC","The present study supports analyses suggesting that Xpert implementation in the United States is cost-effective and can reduce AII duration. .A single-Xpert strategy was cost-saving in a variety of sensitivity analyses, suggesting that replacement of 3 AFB smears with Xpert to determine the need for AII would result in cost savings for most US hospitals.",Cost-effective,15,decision tree model,10
de Bock (2001),The Netherlands,Primary care,Patients presenting with Acute sinusitis in primary care,Wait and see; selective prescription; empirical antibiotics; ultrasound assessment; radiographic assessment,Doxycycline,CEA,Decision tree,Healthcare centre's perspective,Probability of cure,7 days,"NA",No,No,Clinical assessment: DFL 515.59; Ultrasound assessment: DFL 5745.38; Radiographic assessment: DFL 3164.98; Antibiotics: DFL 881.67 costs or savings /patient,Dutch Florins (year NA),"Deterministic sensitivity analysis (DSA), Sensitivity analysis graph (with one parameter varied), Two-way sensitivity analysis graph",The costs for curing one additional patient were DFL516 when antibiotics were selectively prescribed and DFL882 when antibiotics were prescribed immediately,Cost-effective,14,decision tree model,11
Dinh (2018),France,Emergency department,Patients who consulted for community-acquired pneumonia in emergency departments,Pneumococcal urinary antigen test; usual care,"Antimicrobial treatment (penicillin A if Streptococcus pneumoniae), broad-spectrum antibiotics without microbiological identification",CEA,Retrospective real life pragmatic study,Healthcare centre’s perspective,Antibiotic prescriptions saved,"NA","NA",No,Yes,"As only 7 PUA tests led to appropriate antimicrobial modification, we deemed that the potential cost savings, if the test had not been used, would have been 26,244 € during 3 years, that is 8748 € per year.","NA",Deterministic sensitivity analysis (DSA),The test should be used only for patients with probable CAP,Cost-saving,13,trial-based analysis,12
Dugas (2013),USA,Emergency department,Patients presenting  with symptoms of an acute respiratory infection at risk or potentially having influenza-related complications.,Treat none; treat based on provider judgement; treat based on a PCR-based rapid test; treat all,"Antiviral treatment: oseltamivir, zanamivir; antibiotics: amoxicillin/expensive antibiotics",CUA,Decision tree,Societal perspective,Synthesis-based estimates,Lifetime horizon,economic: 0%; health: 3%,Yes,No,PCR: $1389/QALY; treat all: $6246/QALY; treat none: dominated (all compared to provider judgement),US dollars (2011),"Tornado diagram of DSA, CEAC","Assuming a $50,000 per quality-adjusted life-year willingness-to-pay threshold, the most cost-effective treatment option is treatment according to provider judgment from 0% to 3% prevalence, treatment according to a PCR-based rapid influenza test from 3% to 7% prevalence, and treating all at greater than 7% prevalence.",Cost-effective,18,decision tree model,13
Durski (2013),Uganda,Hospital,HIV-infected adults with suspected central nervous system infections,Comprehensive testing; stepwise testing; minimalist testing,2g ceftriaxone intramuscularly once for meningococcal meningitis; five days of ceftriaxone for pneumococcal meningitis.,CEA,Decision tree,Healthcare centre's perspective,percentage of correct diagnosis,"NA","NA",No,No,133 per additional correct diagnosis,"US dollars,  South African Rand (2013)",Deterministic sensitivity analysis (DSA),"Through strategically choosing the order and type of testing coupled with disease prevalence rates, algorithms can deliver more care more efficiently.",Cost-effective,16,decision tree model,14
Giraldez-Garcia (2011),Spain,Primary care,Patients between the ages of 2 and 14 years who consult with a primary care physician due to AP symptoms.,Treat all; clinical scoring; rapid testing; culture; rapid test + culture; clinical scoring + rapid test.,Penicillin; azithromycin (in case of allergy),CEA,Decision tree,Healthcare payer's perspective,Proportion of patients cured without complications from the disease or from any adverse reaction to treatment with penicillin,1 year,"NA",No,No,Only rapid test: 51.22; clinical scoring + rapid test: 50.72 (Costs per patient cured without complications and no adverse reaction to penicillin),NA,"Sensitivity analysis graph (with one parameter varied), Two-way sensitivity analysis graph",The “clinical scoring + rapid test” strategy was the most cost-effective of the six strategies analysed,Cost-effective,15,decision tree model,15
Gonzalez-Canudas (2011),Mexico,Primary care,Patients admitted  with suspected ILI,PCR; diagnosis with influenza RDT + clinical data,Oseltamivir,"CEA, BIA",Decision tree,Healthcare centre's perspective,Synthesis-based estimates,"NA","NA",Yes,No,$12.60 saved each suspected case,US dollars (2009),Fagan nomogram,The use of PR as an aid in the diagnosis of H1N1 influenza increases certainty and reduces the average cost per suspect and infected patient.,Cost-saving,11,decision tree model,16
Harris (2011),South Africa,Primary care,Ambulatory HIV-infected patients in South Africa,"33 diagnostic options, involving combinations of specimen collection methods (oral washes induced and expectorated sputum and bronchoalveolar lavage); PCR or clinical diagnosis with chest x-ray alone","Treatment costs are based on a single, 21-day regimen with oral CTX",CEA,Analysis for decision-making,Healthcare payer’s perspective,"Life years, Proportion of ill patients successfully treated",1 year,"NA",No,No,"At 50% disease prevalence, diagnostic procedures involving expectorated sputum with any PCR method, or induced sputum with nested or real-time PCR, were all highly cost-effective, successfully treating 77–90% of patients at $26–51 per life-year gained.","NA",Deterministic sensitivity analysis (DSA),"Three metrics are relevant: proportion of PCP patients successfully treated, proportion of well persons unnecessarily treated, and the total diagnostic and treatment cost per life-year gained.",Cost-effective,15,not specified,17
Herráez (2017),Spain,Hospital,Patients with suspected TB,Routine TB diagnosis; XPERT,Routine (sensitive) TB treatment,CEA,Decision tree,Healthcare centre's perspective,Synthesis-based estimates,"NA","NA",Yes,No,€2960/QALY,Euros (2016),"Table of DSA, Tornado diagram of DSA, Probabilistic sensitivity analysis (PSA), CEAC","The implementation of a molecular microbiological technique in the diagnosis of tuberculosisis extremely cost-effective compared to the usual method. Its introduction into the routine diagnostic procedure could lead to an improvement in quality care for patients, given that it would avoid both unnecessary hospitalisations and treatments, and reflected in economic savings to the hospital.",Cost-effective,13,decision tree model,18
Holmes (2018),"Wales, UK",Primary care,Adults with symptoms of acute respiratory tract infection (ARTI) for >12 h where the antibiotic decision is unclear,Current standard of care; antibiotic prescribing conditional on POC CRP testing.,Amoxicillin 500 mg three times daily for 7 days.,CEA,Decision tree,Healthcare payer's perspective,QALYs,28 days,"NA",Yes,Yes,"In patients with symptoms of ARTI and based on routine practice, the ICERs of CRP testing were £19,705 per quality-adjusted-life-year (QALY) gained and £16.07 per antibiotic prescription avoided",Pound Sterling (2016),"Deterministic sensitivity analysis (DSA), Table of DSA, Probabilistic sensitivity analysis (PSA), Cost-effectiveness plane of PSA, Cost-effectiveness acceptability curve(s)",The model suggests that as implemented in routine primary care (for all adults with symptoms of ARTI for >12 hours where the antibiotic decision unclear) POC CRP testing is borderline cost-effective.,Cost-effective,17,decision tree model,19
Hunter (2015),England,Primary care,Cohorts of 100 hypothetical patients with RTI,Current GP practice; Three strategies of CRP testing: 1) GP plus CRP; 2) Practice nurse plus CRP; 3) GP plus CRP and communicating training,"Antibiotics at index consultation, antibiotics within 28 days of index, atibotics for subsequent incidents of RTIs after 28 days",CEA,"Decision tree, Markov (compartimental) model",Healthcare payer's perspective,"QALYs, number of antibiotics prescribed and the number of RTIs over 3 years",3 years,economic: 3.5% for costs and benefits (QALYs multiplied by the willingness to pay; health: NA,No,No,The two strategies result in 0.13 additional QALYs per 100 patients and costs 42 pounds less per 100 patients  for the GP plus CRP strategy and 680 pounds less for the nurse plus CRP strategy,Pound Sterling (2012),"Deterministic sensitivity analysis (DSA), Probabilistic sensitivity analysis (PSA), Cost-effectiveness plane of PSA, Cost-effectiveness acceptability curve(s)","Over a 3-year time horizon, GP plus CRP test and nurse plus CRP test have a higher net monetary benefits than current practice. The additional costs of the test is outwighted by cost savings and QALY increment associated with a reduction in infections in the long run.",Cost-effective,18,markov model,20
Jha (2016),South Africa,Laboratory,Patients with (clinically) suspected TB,"Sputum smear microscopy alone; TBDx automated microscopy alone; TBDx automated microscopy,with confirmation of low positive results by Xpert MTB/RIF; TBDx automated microscopy, with confirmation of all positive results by Xpert MTB/RIF; Xpert MTB/RIF performed on all specimens",Non-specified TB therapy (both drug-susceptible and drug-resistant),CEA,Non-specified model,Healthcare payer's perspective,Single-study based estimates,"NA",economic: 3% was used to annualized costs of equipment (no discount rate for outcomes); health: NA,Yes,Yes,"Main outcome reported: $1280 per incremental TB diagnosis, TBDx automated microscopy",US dollars (2015),"Table of DSA, Tornado diagram of DSA, Uncertainty ranges (95%) around results","In settings where universal XpertMTB/RIF is affordable, and health systems are willing to pay at least $1927 per incremental TB diagnosis made, universal Xpert is generally preferred.",Cost-effective,14,not specified,21
Langley (2014),Tanzania,Diagnostic centre,Patients with presumptive TB - different algorithms for patients with and without HIV.,Ziehl-Neelsen (ZN) microscopy; LED fluorescence microscopy; same-day LED fluorescence microscopy; full Xpert rollout; Xpert for known HIV-+ cases; Xpert for HIV-+ cases with additional HIV screening; Xpert for smear-negative and known HIV-+ cases; Xpert for smear-negative and HIV-+ cases with additional HIV testing,Standard regimen; retreatment regimen; resistant TB regimen,CEA,"Discrete-event simulation, Compartmental differential equation model",Healthcare payer's perspective,Synthesis-based estimates,10 years,3%,Yes,Yes,LED microscopy: $29/DALY; same-day LED microscopy: $45/DALY; full Xpert: $169/DALY; others dominated,US dollars (2011),"Table of DSA, Tornado diagram of DSA, Probabilistic sensitivity analysis (PSA), CEAC, 95% credible intervals","We have assessed the effect of several promising tuberculosis diagnostic options that are being considered by many national tuberculosis programmes, and have identified three cost-effective strategies in the context of Tanzania: full rollout of Xpert MTB/RIF (B1), followed by same-day LED fluorescence microscopy (A3) and LED fluorescence microscopy(A2).",Cost-effective,17,descrete-event model,22
Lathia (2018),Canada,Pharmacy,Patients with sore throat,Current standard of care; strep throat POC testing,Antibiotics,CMA,Decision tree,Healthcare payer's perspective,"NA","NA","NA",No,No,-18.66 (province AB); -14.86 (province BC); -12.78 (province NS); -12.47 (province ON); -24.36 (province SK) costs or savings /patient,NA,Deterministic sensitivity analysis (DSA),"This analysis estimates that in a scenario where 60% of patients with severe sore throat seek care in a community pharmacy, compared to a scenario where all patients seek care through a family physician, walk-in clinic or emergency room, the healthcare systems in the five provinces saves a mean of $12.47 to $24.36 per patient.",Cost-saving,12,decision tree model,23
Lavelle (2012),USA,Primary care,Unvaccinated children coming to a physician's office with age-appropriate symptoms of uncomplicated ILI,"No antiviral treatment; rapid testing for influenza, followed by oseltamivir if results are positive; empiric oseltamivir treatment",Oseltamivir,CEA,Decision tree,Societal perspective,Synthesis-based estimates,1 year,"NA",Yes,Yes,"$25,900 to $71,200/QALY, depending on age, compared with the no oseltamivir treatment strategy",US dollars (2008),"Table of DSA, Sensitivity analysis graph (with one parameter varied), CEAC","This analysis demonstrates that when seasonal influenza viruses are circulating in the community and antiviral treatment is clinically indicated, empiric oseltamivir treatment of children who are suspected to have influenza illness may be a cost-effective treatment strategy.",Cost-effective,17,decision tree model,24
Lee (2019),India,"Primary care, Hospital","Adult, HIV-negative patients with presumptive/pulmonary TB",Sputum smear microscopy; Xpert; Truenat; Truenat POC,NA,CEA,Microsimulation model,Health system perspective,Synthesis-based estimates,Lifetime horizon,3%,Yes,Yes,"Truenat POC: 210 /LYG, which dominated all other strategies",US dollars (2017),"Deterministic sensitivity analysis (DSA), Two-way sensitivity analysis graph","Truenat, when replacing smear microscopy and used at point-of-care, increases the number of TB cases correctly detected and linked to care by 590 per 10,000 individuals with presumptive TB. It also increases life expectancy by nearly 0.4 years and is cost-effective",Cost-effective,17,individual-level model,25
Maizia (2011),France,Primary care,Adults (16 years and older) and children (up to 15 years old).,Observation only (reference strategy); clinical scoring; RDT testing; throat culture; clinical scoring combined with RDT testing; RDT testing combined with throat culture; systematic antibiotic therapy.,Amoxicillin penicillin A (6 days) and in case of allergy cefuroxime-axetil (4 days).,CEA,Decision tree,Healthcare payer's perspective,Suppurative complication avoided,"NA","NA",No,No,970 in children and at 903in adults cost per suppurative complication avoided,Euros (2008),"Deterministic sensitivity analysis (DSA), Tornado diagram of DSA","The use of RDT was the most cost-effective strategy from the insurance perspective private US, while the use of culture appeared to be more efficient from the perspective of the system public Medicaid. In acute tonsillitis, in both adults and children, RDT testing by practitioners is the more efficient strategy to identify and treat patients with GAS tonsillitis. Combining RDT testing with throat culture can provide additional effectiveness, but at the cost of a significant extra charge for the community.",Cost-effective,13,decision tree model,26
Mears (2016),England,"Multiple interacting components (laboratory, public health and clinical services)","Population of England, taking into consideration the age distribution of the population and medium TB incidence",National TB strain typing service,"Latent infection treatment (rifampicin, isoniazid, pyridoxine); management of active disease (rifater, ethambutol, rifanah, pyridoxine)",CEA,Dynamic deterministic compartmental models,Public sector perspective,Synthesis-based estimates,20 years,3.5000000000000003E-2,No,No,"₤95,628/QALY (LTBI detecting increase from 3% to 4%); ₤54,539/QALY (LTBI detecting increase from 3% to 13%); cost-saving if diagnostic delay was reduced with 1 week",Pound sterling (unknown year),"Table of DSA, Sensitivity analysis graph (with one parameter varied)","This analysis failed to demonstrate that the TB-STS is a cost-effective use of NHS resources. It suggests that it is unlikely that earlier identification of false positive cases related to laboratory contamination, or increases in the identification and prophylactic treatment of contacts with a latent infection could, on their own, justify the cost of the system.",Not cost-effective,17,dynamic model,27
Menzies (2012),"Botswana, Lesotho, Namibia, South Africa, and Swaziland",Health facility,General population (with dynamic model). For TB diagnosis patients presenting to a health facility with suspected TB,Current diagnostic algorithms; implementing Xpert in accordance with current WHO recommendations,Non-specified TB therapy,CEA,Dynamic compartmental model,Healthcare payer's perspective,Synthesis-based estimates,20 years,3%,Yes,Yes,$784/DALY; $810/life-year saved,US dollars (2011),"Table of DSA, Tornado diagram of DSA, Three-way sensitivity analysis graph, CEAC, uncertainty interval (2.5 and 97.5 percentiles)","Along with the projected health benefits of scaling up Xpert will come significantly increased demands on healthcare resources. The large increase in funding required under the Xpert scenario raises the question of affordability. Although our cost-effectiveness results suggest that the introduction of Xpert represents good value for money according to typical international benchmarks, it does not automatically follow that TB program budgets will be able toabsorb these changes.",-,16,dynamic model,28
Mewes (2019),USA,"Hospital, ICU",Patients with suspected sepsis on the ICU and patients hospitalized with LRTI.,Standard care; PCT-guided care,NA,CEA,Decision tree,"Societal perspective, Healthcare centre's perspective",Synthesis-based estimates,The length of the hospital stay,"NA",Yes,Yes,The incremental savings per antibiotic day avoided were -$584 for the PCT group,US dollars (2017),"Deterministic sensitivity analysis (DSA), Tornado diagram of DSA",Using a Procalcitonin-algorithm to guide antibiotic use in sepsis and hospitalised lower respiratory tract infection patients is expected to generate cost-savings to the hospital and lower rates of antibiotic resistance and C.difficile infections.,Cost-effective,16,decision tree model,29
Michaelidis (2013),USA,Primary care,Two hypothetical cohorts were modeled in separate trial-based analyses: adults with ARTIs judged by their physicians to require antibiotics and all adults with ARTIs.,Procalcitonin-guided antibiotic therapy; usual care.,Empiric antibiotic prescription,CEA,Decision tree,Health care system perspective,"QALYs, Antibiotic prescriptions saved",ARTI treatment episode as the time horizon,"NA",Yes,Yes,149 / antibiotic prescription saved,US dollars (2012),"Probabilistic sensitivity analysis (PSA), Cost-effectiveness acceptability curve(s)","Procalcitonin testing is unlikely to be preferred over usual care when costs alone are considered, but is likely to be cost-effective when the costs of antibiotic resistance are considered and the test is used only in adults with ARTIs judged to require antibiotics by their physicians.",Cost-effective,16,decision tree model,30
Naidoo (2016),South Africa,Laboratory,Patients with presumptive TB,A smear/culture-based algorithm; an Xpert-based algorithm,Not specified,"Cost Analysis, CEA",Unspecified costing tool,Laboratory perspective,Single-study based estimates,"NA",economic: 3% for equipment; health: NA,No,Yes,$6274 per additional MDR-TB case diagnosed,US dollars (2013),-,"The introduction of the Xpert-based algorithm has resulted in substantial increases in cost which are in line with modelling exercises undertaken in South Africa. However these were not matched by an increase in TB diagnostic efficacy; massive cost increases persist even when temporal trends of a possible declining TB prevalence were taken into consideration. One of the benefits of the Xpert-based algorithm was the modest increase in the number of MDR-TB cases diagnosed, which comes at high cost.",-,16,not specified,31
Nelson (2015),USA,Emergency department,Children presenting with ILI,Rapid multiplex PCR; traditional PCR; direct-fluorescentantibody staining; 4: rapid antigen tests.,Antibiotics; antivirals (not further specified),CEA,Decision tree (not explicitly stated),Healthcare centre's perspective,Single-study based estimates,Lifetime horizon,Economic: NA; health: 3%,Yes,No,"PCR: $115,556/QALY in children aged 3-36 months, and $228,000/QALY in children aged 3-18 yrs (other alternatives were dominated)",US dollars (2011),"Sensitivity analysis graph (with one parameter varied), CEAC","A rapid multiplex PCR strategy was not only the most effective strategy in terms of maximizing patient QALYs, but was also the most expensive.",Cost-effective,15,decision tree model,32
Neuner (2003),USA,Primary care,Adults in the general U.S. population.,Observation without testing or treatment; empirical treatment with penicillin; throat culture using a two-plate selective culture technique; optical immunoassay (OIA) followed by culture to confirm negative OIAtest results; OIA alone.,Penicillin at a dosage of 250 mg four times a day for 10 days.,CEA,Decision tree,Societal perspective,QALYs,1 year,"NA",Yes,No,Culture strategy: 0.2668 quality-adjusted life-day lost and an average cost of $6.66 per patient,US dollars (2000),"Deterministic sensitivity analysis (DSA), Probabilistic sensitivity analysis (PSA)","Although the other four strategies had similar effectiveness (all resulted in about 0.27 lost quality-adjusted life-day), culture was the least expensive strategy.",Cost-effective,15,decision tree model,33
Nicholson (2014),UK,Hospital,"People presenting to medical admissions units, or any ward accepting acute medical admissions, with an acute exacerbation of chronic cardiopulmonary illness of ≤ 168 hours’ (7 days’) duration or an acute cardiopulmonary illness of ≤ 7 days’ duration",Point-of-care tests (POCTs) for influenza A and B and pneumococcal infection; reverse transcriptase-polymerase chain reaction (RT-PCR) tests for influenza A and B and RSV A and B; and conventional culture for these pathogens.,"Broad-spectrum antibiotics (cephalosporins, co-amoxiclav, piperacillin with tazobactam, carbapenems, quinolones, tetracyclines, cotrimoxazole, clarithromycin, azithromycin and clindamycin); narrow-spectrum antibiotics (Gram-positive antibiotics benzylpenicillin, flucloxacillin, amoxicillin (and ampicillin), erythromycin, vancomycin, rifampicin, fusidic acid, linezolid, daptomycin, gram-negative antibiotics, gentamicin and other aminoglycosides, aztreonam, trimethoprim, nitrofurantoin, anaerobic antibiotics and metronidazole).",CEA,Randomised controlled trial (RCT),Healthcare centre's perspective,"QALYs, EQ-5D; proportion of patients who are prescribed antibiotics; time to treatment",28 days,"NA",No,No,734717 per QALY,Pound Sterling (2007),"Deterministic sensitivity analysis (DSA), Table of DSA, Probabilistic sensitivity analysis (PSA), Cost-effectiveness plane of PSA, Cost-effectiveness acceptability curve(s)","The total costs and QALYs of each diagnostic strategy were similar, although, incrementally, PCR was the most cost-effective strategy. The analysis does not support routine use of point-of-care tests for either influenza or pneumococcal antigen for adults presenting with acute cardiopulmonary conditions, but suggests that conventional viral culture for clinical diagnosis should be replaced by PCR.",Cost-effective,16,trial-based analysis,34
Nshimyumukiza (2016),Canada,Outpatient clinic or emergency department,Quebec (Canada) population,Current care; potential rapid POC test,Oseltamivir,CEA,"Dynamic deterministic compartmental models, Agent-level Markov model (SPLMM)",Societal perspective,Synthesis-based estimates,1 year,"NA",Yes,No,"$7573 saved /100,000 person years and 1.92 life-years saved /100,000 person years",Canadian dollars (2011-2012),"Tornado diagram of DSA, CEAC","Considering the baseline values of sensitivity, specificity, and cost to be 74%, 99%, and $25, respectively, for a POC test; the antiviral treatment based on this test appears dominant as compared to empirical antiviral treatment based on clinical judgment.",Cost-effective,16,individual-level model,35
Oostenbrink (2002),The Netherlands,"Hospital, Pediatric Emergency Department",Children (1 month to 15 years) visiting the pediatric emergency department of a hospital with meningeal signs,"Practice a lumbar puncture, based on the characteristics of the patient’s history, physical examination and serum C-reactive protein (CRP) ; do not practice this",Antibiotics,CUA,Decision tree,Societal perspective,Hospitalizations saved,15 years,0.04,No,No,"€ 401,965 per QALY (Streptococcus pneumoniae) and €22,635 per QALY (Neisseria meningitidis)",Euros (2001),Deterministic sensitivity analysis (DSA),"Minimizing lumbar punctures and empirical treatments using a diagnostic decision rule, without missing a single case of meningitis, was a dominant strategy to actual practice.","Cost-effective, not generalizable for vaccination strategies.",17,decision tree model,36
Oostenbrink (2003),The Netherlands,Hospital,360 children from one month up to fifteen years of age visiting the emergency department of a hospital with meningeal signs between 1988 and 1998,"Diagnostic decision rule, based on a clinical score and a CSF score (cell count in cerebrospinal fluid) for lumbar puncture and empirical treatment for bacterial meningitis; current practice (a low threshold to perform a lumbar puncture, and empirical treatment)",3rd generation cefalospsorin; amoxicilin; bemzylpenicilim,CA,Cost-minimization analysis,Healthcare centre's perspective,QALYs,"NA","NA",No,No,Total costs current practice €2.976; total costs decision rule €2.684,Euros (2001),Deterministic sensitivity analysis (DSA),"The decision rule reduced total costs by 292 euros per patient, 33 euros in the diagnostic phase and 259 euros in the treatment course.The application of the decision rule reduced the number of patients hospitalized.",Cost-saving,14,not specified,37
Oppong (2013),Norway and Sweden,Primary care,"Patients aged ≥18 years presenting to their GP for the first time with an acute or worsened cough as the main or dominant symptom for up to 28 days, or who had a clinical presentation suggesting lower respiratory tract infections.","Rapid test, point-of-care C-reactive protein.",Antibiotics,CEA,Hierarchical regression,Healthcare centre's perspective,"QALYs, Days free from disease, EQ-5D, symptom information (case report forms).",28 days,"NA",No,No,"€112,7 / antibiotic prescription saved",Euros (2007),Cost-effectiveness acceptability curve(s),Patients receiving POCCRP did not have significantly different measures of recovery or outcomes compared to patients not receiving this test.,"Cost-effective, reduces the rate of antibiotic prescribing.",17,regression model,38
Oppong (2018),"Belgium, United Kingdom, Netherlands, Poland and Spain",Primary care,"Patients presenting with respiratory tract infections in primary care, from Belgium, the Netherlands, Poland, Spain and the UK (England and Wales).",CRP; communication skills; CRP and communication skills combined; usual care,Antibiotics,CEA,Multilevel (regression) model,Healthcare payer's perspective,"QALYs, EQ-5D",28 days,"NA",Yes,Yes,Communication skills was associated with an ICER of €68.08 per percentage reduction in antibiotic prescribing when compared with usual care. The ICER for CRP compared with communication skills was €176.53 and the ICER for the combined intervention compared with CRP was €338.89,Euros (2016),"Deterministic sensitivity analysis (DSA), Probabilistic sensitivity analysis (PSA), Cost-effectiveness plane of PSA, Cost-effectiveness acceptability curve(s)","In terms of cost per percentage reduction in antibiotic prescribing, overall, communication skills was the most cost-effective intervention. Similarly, the CUA also showed that communication skills was the most cost-effective intervention.",Cost-effective,15,regression model,39
Ost (2003),United States,ICU,Immunocompetent patients in the intensive care unit,Empiric treatment only; quantitative nonprotected endotracheal cultures; bronchoscopy; nonbronchoscopic mini-bronchoalveolar lavage (mini-BAL),Antibiotics,CEA,Decision tree,Healthcare centre’s perspective,Hospital survival,28 days,"NA",No,Yes,No. of Initial Antibiotics: Zero: Empiric=Na; Empiric + ETT asp=72847; Empiric + mini-BAL=101479; Empiric + FOB=433261; One antibiotic: Empiric=Na; Empiric + ETT asp=20734; Empiric + mini-BAL=86184; Empiric + FOB=634288; Two antibiotics:Empiric + ETT asp=NA; Empiric + mini-BAL=4854; Empiric + FOB=819710; Empiric=dominated; Three antibiotics: Empiric + mini-BAL=NA; Empiric + ETT asp= dominated; Empiric + FOB= 1375978; Empiric= Dominated,"NA","Deterministic sensitivity analysis (DSA), Two-way sensitivity analysis graph, Three-way (or more) sensitivity analysis graph, Probabilistic sensitivity analysis (PSA)","From the perspective of minimizing cost, minimizing antibiotic use, and maximizing survival, the best strategy was three antibiotics with mini-BAL.",Cost-effective,14,decision tree model,40
Perone (2007),Switzerland,Primary care,372 patients over 15 years of age who were referred for a sore throat were included between March 1999 and September 2001 if their clinical score was between two and four points.,Rapid test systematique then antibiotic therapy if the test is positive; quick test if the score is 2 or 3 then antibiotic to patients with a positive result or a clinical basis of 4; empiric antibiotic therapy to patients with a clinical score of 3 or 4.,Ten-day penicillin.,CA,Decision tree,Healthcare centre's perspective,Rate of appropriate use of an antibiotic per patients treated,"NA","NA",No,No,$15.30 (rapid test strategy) per patient,NA,Deterministic sensitivity analysis (DSA),The results of this study is that the rapid test is a valid method for the diagnosis of GABHS. The best clinical strategy for the diagnosis and treatment of pharyngitis in adults is the rapid systematic test in patients with a clinical population greater than or equal to two.,Cost-effective,11,decision tree model,41
Pinto (2016),Brazil,Primary care,Presumptive TB patients undergoing an initial consultation,"Standard of care (presumptive TB patients undergoing an initial consultation, a chest X-ray, two SSM examinations and HIV testing, those with HIV co-infection undergo culture and DST); SSM testing of two samples was replaced by Xpert testing of one sputum sample",The WHO-recommended standard first-line drug regimen,CEA,Decision tree,National TB programmes perspective,Synthesis-based estimates,"NA",No discounting,Yes,No,$943 per additional TB diagnosis;  US$356 per additional TB diagnosis with bacteriological confirmation,US dollars (2014),"Table of DSA, Tornado diagram of DSA, Two-way sensitivity analysis graph, PSA: uncertainty ranges","Xpert is more costly than SSM, but has been shown to be more accurate, and potentially more costeffective in low and high-burden countries with high MDR-TB and HIV co-infection rates. In a setting with low MDR-TB and moderate HIV coinfection rates such as Brazil, implementation of single-sample Xpert testing replacing two-sample SSM tests would result in a modest increase (US$1.2 million per year, or 1.7% of Brazil’s NTP budget) in total health system costs for the additional TB confirmation of 3344 patients.",-,15,decision tree model,42
Pooran (2019),"South Africa, Zambia, Zimbabwe, Tanzania",Primary care,Patients with presumptive tuberculosis,Same-day smear microscopy; POC Xpert,(Unspecified) TB treatment,CEA,Trial-based,Healthcare provider's perspective,Single-study based estimates,"NA",economic: Equipment etc: 3%; health: NA,Yes,No,Incremental costs per clinical outcome: diagnosed by index test: 4186; starting treatment: 1464; starting treatment same day: 561; completing treatment: 1211; improved morbidity: 1918,US dollars (2014),"Tornado diagram of DSA, Cost-effectiveness acceptability curve(s)",Point-of-care Xpert is likely to be cost-effective in settings willing to pay at least $4500 per treatment initiation or $3800 per treatment completion among culture-positive patients,Cost-effective,14,trial-based analysis,43
Rodriguez‐Martinez (2019),Colombia,Hospital,Patients 12 months of age and younger who were admitted  for acute bronchiolitis,"“good practice”, which included adherance to diagnosis guidelines (including: hemogram, C‐reactive protein, procalcitonin, chest radiography, and tests for detection of respiratory viruses); ""bad practice""","Inhaled or nebulized beta 2 agonists, inhaled or nebulized anticholinergics, nebulized epinephrine, inhaled corticosteroids, systemic corticosteroids, antibiotics, and nebulized hypertonic saline",CEA,Decision tree,Healthcare centre's perspective,Synthesis-based estimates,1.5 years,"NA",Yes,No,"""Good practice"" was dominant","US dollars, Colombian pesos (COP) (2015)","Deterministic sensitivity analysis (DSA), Tornado diagram of DSA","Compared with lack of “good practice,” the utilization of “good practice” in the diagnosis and management of patients with bronchiolitis was associated with both fewer patients readmitted within 10 days of post discharge (0.88 vs 0.99 on average per patient) and lower costs (US$1529.3 versus $1709.1 average cost perpatient), thus leading to dominance",Cost-effective,14,decision tree model,44
Rothberg (2003) - 1,USA,Physician's office,"Unvaccinated, healthy, working adults aged 20-50, presenting with influenza-like illness during the influenza season",No diagnostic test; Directigen (influenza A/B); FLU OIA; QuickVue; ZstatFlu,Amantadine; rimantadine; oseltamivir; zanmivir; azithromicin; amoxicillin,CUA,Decision tree,Societal perspective,Synthesis-based estimates,5 days,"NA",No,No,All testing strategies are dominated by empiric treatment with amantadine,US dollars (2001),DSA,The economic impact alone validates the use of antiviral therapy in healthy adults with influenza-like illness. The small benefit of shortening symptoms by an average of 1 day is by no means trivial.,"Cost-saving, Cost-effective",15,decision tree model,45
Rothberg (2003) - 2,USA,Primary care,"Persons aged >65 years, presenting with influenza symptoms during the influenza season",Current care; Quickvue,Amantadine; zanamivir; oseltamivir; rimantidine,CUA,Decision tree,Societal perspective,Synthesis-based estimates,Lifetime horizon,"NA",Yes,No,"Amantadine treatment only: $1129/QALY; test-treat oseltamivir: $5025/QALY, empiric oseltamivir: $10,296/QALY, other test-treat combinations (extended) dominated",US dollars (2001),"Sensitivity analysis graph (with one parameter varied), Two-way sensitivity analysis graph, PSA","Under most circumstances, antiviral therapy is reasonably cost-effective and within the range of other widely accepted interventions for older adults. The optimal strategy, however, depends on the patient’s vaccination status, the probability that he or she has influenza, and the risk for hospitalization",Cost-effective,14,decision tree model,46
Rothberg (2005),USA,Primary care,"Healthy children at ages 2, 7 and 15 years",Quickvue; ZstatFlu,Amantadine; oseltamivir; amoxicillin,CEA,Decision tree,Societal perspective,Synthesis-based estimates,Lifetime horizon,"NA",Yes,No,Antiviral therapy: $800 - $1800/QALY; testing stategies were dominated in most scenarios,US dollars (2003),"Sensitivity analysis graph (with one parameter varied), PSA","During local influenza outbreaks, children with symptoms of ILI benefit from antiviral therapy if it is initiated within 48 hours of symptom onset. At the same time, antiviral therapy saves money if parents return to work sooner. In that case, there is no trade-off between cost and effectiveness.",Testing not cost-effective - empirical treatment is cost-effective,14,decision tree model,47
Schuetz (2015),USA,Hospital,The patient population in this study is patients with suspected ARIinfection diagnoses seen in one of three settings: inpatient hospitalsetting (not in the intensive care unit - ICU); hospital ICU; outpatient clinic or emergency department (ED) based on the meta-analysis data,PCT testing and monitoring; usual care,"Typical dosages and mix of expected therapy were derived frompublished clinical treatment guidelines (many references, but nothing explicit)",CA,Decision tree,Healthcare payer's perspective,"NA",30 days,"NA",No,Yes,"The costs of PCT-guided care for the one million member cohort was $2,083,545, compared to $2,780,332 for the usual care group, resulting in net savings of nearly $700,000 costs or savings /patient",US dollars (2014),"Deterministic sensitivity analysis (DSA), Sensitivity analysis graph (with one parameter varied)","The results show substantial savings associated with the use of PCT to guide antibiotic treatment of ARI in common US treatment settings. Across all three settings PCT-guided care is associated with net savings ranging from $73,326 in the ICU to  > $5 million in the outpatient clinic and ED setting, for total savings to the IDN of more than $6 million.",Cost-saving,14,decision tree model,48
Schwarzinger (2003),USA,Primary care (not stated specifically),Healthy working adults younger than 65 years of age who consult within 2 days of the onset of influenza-like symptoms,No zanamivir; test with zanamivir; systematic zanamivir,Nanamivir; (unspecified) antibiotics,CBA,Decision tree,Societal perspective,Synthesis-based estimates,Duration of influenza-like illness,"NA",No,No,test: $-14.40 for 0.65 averted influenza days; empiric treatment: $-29.80 for 0.81 averted influenza day (1),US dollars (1999),"Table of DSA, Sensitivity analysis graph (with one parameter varied)","During influenza epidemics, when unvaccinated healthy working adults consult within 2 days of the onset of influenza-like symptoms, systematic zanamivir prescription without rapid influenza test is a dominant strategy from a societal perspective.",Cost-saving,16,decision tree model,49
Shah (2013),Uganda,"Primary care, Hospital",HIV-infected individuals presenting with signs/symptoms of active TB disease,ZN smear-microscopy testing of two sputa; same as 1 plus one urine sample for point-of-care LF-LAM testing; Xpert on one sputum (rifampin resistance is confirmed with conventional culture and DST for all patients); same as 3 plus one urine sample for point-of-care LF-LAM testing,TB treatment; TB treatment category 2; MDR-TB treatment; Annual HIV care costs,CEA,Decision tree,Healthcare payer's perspective,Single-study based estimates,Lifetime horizon,3%,No,No,ZN microscopy + urine sample testing: $33/DALY; Xpert on one sputum: $58/DALY; Xpert on one sputum + urine sample testing: $57/DALY (ZN microscopy as reference),US dollars (2013),"Sensitivity analysis graph (with one parameter varied), CEAC","Compared with an algorithm of Xpert testing alone, the combination of Xpert with LFLAM was considered highly cost-effective. Addition of urine LF-LAM testing to smear-microscopy was a less effective strategy than Xpert replacement of smear-microscopy, but was less costly and also considered highly cost-effective compared with continued usage of smear-microscopy alone.",Cost-effective,16,decision tree model,50
Shen (2016),China,Primary care,"Children aged 18 years or below with ILI, had symptoms and signs compatible with influenza.",No antiviral therapy; 2: post influenza RDT treatment; 3: empiric treatment,Oseltamivir,CEA,Decision tree,Healthcare payer's perspective,Synthesis-based estimates,"NA","NA",No,No,"32,810/QALY",Chinese yuan (no year),"Tornado diagram of DSA, cost-effectiveness plane",The empiric oseltamivir treatment of children who are suspected to have influenza illness may be a dominant or a very cost-effective treatment strategy in comparison against post RIDT treatment with oseltamivir and no antiviral therapy.,Not cost-effective,13,decision tree model,51
Siddiqui (2008),UK,Primary care,Patients presenting with ILI,Do not treat with antiviral drugs; treat all patients with antiviral drugs; test then treat those who test positive,Oseltamivir,CEA,Decision tree,Healthcare payer's perspective,Synthesis-based estimates,"NA",3.5000000000000003E-2,Yes,No,For stockpiling: ₤1900 and ₤13700/QALY for the 1918 and 1957/69 scenarios; test-treat ₤31000 and ₤228000/QALY,Pound Sterling (2004),"Tornado diagram of DSA, Sensitivity analysis graph (with one parameter varied), cost-effectiveness plane",Near-patient testing is unlikely to be a cost-effective approach to conserving AV stocks but might be considered early in a pandemic. A more cost-effectivestrategy would be to increase the stockpile of AV drugs.,Not cost-effective,14,decision tree model,52
Smith (2002),USA,"NA",32-year old patients with typical influenza symptoms and a temperature 37.8°C during an influenza season. Other age categories in sensitivity analysis.,No antiviral testing or treatment; oseltamivir/zanamivir treatment without testing; empiric rimantadine; empiric amantadine; test-treat oseltamivir/zanamivir; 6: test-treat rimantadine; 7: test-treat amantadine,Oseltamavir; zanamivir; rimantadine; amantadine,CEA,Decision tree,"Societal perspective, Healthcare payer's perspective",Synthesis-based estimates,Single episode of illness,"NA",Yes,No,Empiric amantadine: $9.06 per illness day avoided; empiric oseltamivir: $198 per illness day avoided; other strategies (extended) dominated,US dollars (2000),"Tornado diagram of DSA, CEAC","Amantadine, zanamivir, and oseltamivir cost about $250 or less per quality-adjusted day gained or illness day avoided for patients with fever and typical influenza symptoms. Rapid testing was, forthe most part, more costly and less effective than treatment without testing.","""Economically reasonable""",12,decision tree model,53
Sohn (2019),India,District TB and microscopy center,Patients presenting to care for TB diagnosis,Centralized Xpert; decentralized Xpert,Unspecified treatment for sensitive and resistant TB,CEA,Individual-contact model / agent-based model,Healtcare system perspective,Synthesis-based estimates,10 years,3%,Yes,Yes,3161 /DALY,US dollars (2015),"Sensitivity analysis graph (with one parameter varied), Cost-effectiveness acceptability curve(s)","Provided that decentralized testing can be performed with equal quality as centralized testing, the costs and LTFU incurred by using a hub-and-spoke system are likely to justify the increased costs of decentralized testing, except in settings where testing volumes is low.",Not clear,16,individual-level model,54
Stankiewicz (2003),USA,Primary care,One hundred patient were evaluated for criteria meeting the subjective diagnostic criteria for chronic rhinosinusitis as developed by the Task Force for Acute and Chronic Rhinosinusitis,Subjective-based diagnosis; diagnosed with a screening CT scan.,Amoxicillin or cefuroxime.,CA,Individual sampling model,Healthcare centre's perspective,Costs saved,"NA","NA",No,No,147 per patient,"NA","NA","With screening CT scanning, patients are diagnosed more accurately, according to whether they have disease or not. This is important because the current subjective method of diagnosis of chronic rhinosinusitis is inaccurate.",Cost-saving,10,trial-based analysis,55
Stojanovic (2017),China,"Primary care, Emergency department, Hospital",Patients with suspected ARI infection diagnoses seen in one of three settings (subgroups): (1) inpatient hospital setting (not in the ICU); (2) hospital ICU; (3) outpatient clinic or emergency department (ED).,Usual care; PCT testing and monitoring,Antibiotic days (ABs),BIA,Decision tree,Healthcare centre's perspective,Reduction in antibiotic days,30 days,"NA",No,Yes,"In the inpatient setting, the costs of PCT-guided care compared to usual care resulted in net savings of 721,563 CNY Chinese hospital system; In the ICU and outpatient settings, savings were 250,699 CNY and 2.4 million CNY, respectively. The overall annual net savings of PCT-guided care was nearly 3.4 million CNY",Chinese yuan (2015),Deterministic sensitivity analysis (DSA),Our results demonstrate substantial savings associated with the use of PCT to guide antibiotic treatment of ARI across common China treatment settings.,Cost-saving,17,decision tree model,56
Suen (2015),India,Public sector clinics and private clinics,"Individuals are followed from birth to death, TB suspects for TB diagnosis",current standard of care; Xpert for DST; Xpert for initial diagnoses and DST in public clinics; PPM; PPM combined with GeneXpert for DST; PPM combined with GeneXpert for initial diagnoses and DST in public clinics,"Various treatment courses (categories 1,2 and 4)",CEA,Dynamic transmission microsimulation model,Societal perspective,Synthesis-based estimates,Lifetime horizon,0.03,Yes,Yes,PPM: $72/QALY; PPM + Xpert: 145/QALY; PPM + Xpert in public clinics: 1104/QALY (others dominated),US dollars (2013),"CEAC, partly PSA (on the simultaneous effect of uncertainty about the quality of life lost due to TB and the costs of care)","Our results illustrate that there is no silver bullet for combating the TB epidemic -- introducing rapid and accurate diagnostic systems, either for initial diagnosis or DST, will have limited ability to control the epidemic and, in a context where PPM is available, is not cost-effective if implemented without substantial effort to bring the fragmented public and private treatment systems together.",Cost-effective,16,individual-level model,57
Takwoingi (2019),United Kingdom,Hospital,Adults presenting with suspected active TB,"QFT-GIT; TSPOT.TB; reference standard (minimum set of tests defined by the NICE guideline, verified by a panel of blinded clinicians)","Rifampicin, isoniazid, pyrazinamide, ethambutol hydrochloride",CUA,Decision tree,Healthcare payer's perspective,Synthesis-based estimates,60 days,"NA",Yes,No,Varying from 6640 to 22010 /QALY,Not reported,"Cost-effectiveness plane of PSA, Cost-effectiveness acceptability curve(s)","The use of current IGRA tests for ruling out active TB would be unlikely to be considered cost-effective if a QALY were to be valued at £20,000 or £30,000. There are cost savings, but the health detriment is large because of the delay in diagnosing active TB.",Not cost-effective,16,decision tree model,58
Tillekeratne (2019),Sri Lanka,Emergency department,ILI patients,Influenza clinical prediction tool; targeted rapid influenza testing; universal rapid influenza testing,Amoxicillin; oseltamivir,CEA,Decision tree,Societal perspective,Synthesis-based estimates,An ILI treatment episode,"NA",Yes,Yes,"The incremental cost per antibiotic prescription avoided with clinical prediction versus standard care was US$3.0, which was lower than the base-case estimate of the cost of antimicrobial resistance per ILI antibiotic prescription (US$12.5)",US dollars (2014),"Deterministic sensitivity analysis (DSA), Probabilistic sensitivity analysis (PSA)","Standard care was less expensive than other strategies across all parameter values in one-way sensitivity analyses. To obtain a cost-effectiveness ratio lower than US$12.5 with targeted testing versus standard care, the test price must be <US$2.6. At a higher threshold of US$28.7, the test price must be <US$7.7.",Cost-saving,16,decision tree model,59
Van Howe (2006),USA,Primary care,Children and adolescents presenting with pharyngitis.,Observe without testing or treatment; treat all suspected cases with antibiotics; treat those with positive throat cultures; treat those with positive rapid tests; treat those with positive rapid tests and those with positive throat cultures after negative rapid tests; use a clinical scoring measure to determine the diagnosis/treatment strategy.,Penicillin; cephalosporin.,CUA,Decision tree,Societal perspective,QALD—quality-adjusted life-day,"NA",0.03,Yes,No,"$32,132.01 rapid antigen testing had the best cost-utility. It dominated both ""treat all"" and ""rapid test + culture"" strategies",US dollars (2003),"Table of DSA, Tornado diagram of DSA, Probabilistic sensitivity analysis (PSA)","When the cost of a culture is low, in comparison with a paid test, culturing samples for all children may be the best option. As the cost of throat cultures increase, relative to the price of a rapid test, the rapid test becomes the better option.",Cost-effective,15,decision tree model,60
Van Rie (2013),South Africa,Primary care,"individuals with prolonged (>2 weeks) cough and/or other TB symptoms, presenting at a primary care clinic",Smear plus culture; Xpert,Not specified,Cost Analysis,Standard descriptive statistics,Not specified,Single-study based estimates,"NA",economic: 5% (capital goods); health: NA,No,No,Cost savings of $3.28 per valid Xpert result,US dollars (2010),-,"The cost per Xpert was only US$1.88 higher than the cost for smear microscopy and culture, and US$14.05 higher than smear microscopy only. Due to the low error rate, the cost per valid Xpert result was US$3.28 lower than the cost per valid smear microscopy plus culture result. The cost per case diagnosed was similar for both strategies (US$266 vs. US$260).",Cost-saving,14,trial-based analysis,61
Vassall (2011),"India, South Africa, Uganda","NA",Individuals suspected of having TB,"Two sputum microscopy, followed by clinical diagnosis that might include chest Xray and antibiotic trial; Xpert after two negative smear examinationss; Xpert instead of smear examination","Specified treatment protocol of TB treatment, also including what to to if resistance is found",CEA,Decision tree,Healthcare payer's perspective,Synthesis-based estimates,"NA",economic: 3%; health: NA,Yes,Yes,"Xpert after two negative smear examinations: India: $55/DALY, South Africa: $110/DALY, Uganda: $41/DALY; Xpert instead of smear examination: India: $68/DALY, South Africa: $138/DALY, Uganda: $37/DALY",US dollars (2010),"Table of DSA, Sensitivity analysis graph (with one parameter varied), Three-way  sensitivity analysis graph, CEAC",Our results suggest that Xpert is likely to be more cost-effective than a base case of smear microscopy and clinical diagnosis of smear-negative TB.,Cost-effective,16,decision tree model,62
Walusimbi (2016),Uganda,Primary care,"The study population comprised adult HIV-infected patients older than 18 years, with presumptive active pulmonary TB",Microscopic observation drug susceptibility (MODS) assay; Xpert MTB/Rif test.,Not specified,CEA,Decision tree,Healthcare centre's perspective,Synthesis-based estimates,"NA",economic: 3%; health: NA,No,No,MODS: $34 per TB patient diagnosed; Xpert: $71 per TB patient diagnosed,US dollars (2014),"Table of DSA, Tornado diagram of DSA","The algorithm using MODS was more cost-effective compared to the algorithm using Xpert for a wide range of different values of accuracy, cost and TB prevalence. The cost (threshold value), where the algorithm using Xpert was optimal over the algorithm using MODS was $5.92",Cost-effective,16,decision tree model,63
Wang (2019),China,Hospital,Pulmonary and extrapulmonary TB suspect patients,Single vs. repeated Xpert assay,NA,CEA,Trial-based (no model),NA,Single-study based estimates,"NA","NA",No,Yes,Pulmonary: 467.72; extrapulmonary: 291.87 per additional TB diagnosis,Not reported,NA,The cost-effectiveness analysis showed that the incremental cost of performing a second Xpert was very high for the smear-positive TB patients,Not cost-effective,12,trial-based analysis,64
Wikman (2017),Mozambique,Primary care,TB suspects,"Sputum smear microscopy (SM, base case); Xpert replacing SM; Xpert after smear-negative SM; microscopic observation drug-susceptibility (MODS) as a replacement; MODS as an add-on for smear-negative SM",Non-specified TB therapy,CUA,Markov (compartimental) model,Healthcare provider's perspective,Synthesis-based estimates,90 years,3%,Yes,No,SM + MODS: $5648/DALY;  MODS: $5375/DALY; SM + Xpert: $346/DALY; Xpert: $122/DALY,US dollars (2013),"Tornado diagram of DSA, Probabilistic sensitivity analysis (PSA), CE plane","Our results suggest that in this rural African setting substituting SM by Xpert MTB/RIF would be the most cost-effective strategy compared to its implementation as an add-on strategy or MODS implementation. However, the degree of uncertainty is high.",Cost-effective,15,markov model,65
Xie (2017),Canada,Hospital,Hospitalized community acquired pneumoniae,BinaxNow-SP and culture; culture alone,Ceftriaxone plus azithromycin for empirical treatment; penicillin G for tretment of SP,CEA,Decision tree,Healthcare centre’s perspective,Case correctly classified,3 days,"NA",Yes,No,Incremental cost per patient 36 dollars. Incremental costs per case correctly classified 582 dollars,Canadian dollars (year unknown),Deterministic sensitivity analysis (DSA),An overall increase in diagnostic accuracy of 6.2% due to the addition of BinaxNOW‐SP.,Cost-effective,13,decision tree model,66
Yakhelef (2014),Kenya,Hospital,Patients with a cough of at least 2 weeks and two negative smears,"Conventional diagnostic algorithm (based on clinical findings, radiological features and an antibiotic trial); culture-based algorithm that uses TLA and LJ cultures in addition to the conventional algorithm",Non-specified TB therapy,CEA,No model,Healthcare centre's perspective,Single-study based estimates,"NA","NA",No,No,Varying between €452-€3121 per case depending on exact algoritm used,Euros (2009),DSA,"Using TLA/LJ in addition to the conventional algorithm made it more expensive, although its cost-effectiveness would improve if the number of screened patients increased. The decision to adopt rapid culture for TB epends on the government/community’s willingness to pay for it.",culture-based algorithm may be hard to afford for resource-limited countries,15,not specified,67
You (2012),China (Hong Kong),Hospital,"Adult patients hospitalized for severe respiratory infection, suspected of influenza","Immunofluorescence assay; PCR testing; empirical antiviral treatment plus PCR, to later continue or discontinue treatment based on test result; empirical antiviral treatment",Oseltamivir,CEA,Decision tree,Healthcare provider,Synthesis-based estimates,Lifetime horizon,0.03,Yes,No,Empirical treatment dominates testing,US dollars (2011),"Two-way sensitivity analysis graph, CEAC","In a season when the ‘seasonal influenza’ virus strains are predominant, ‘‘empirical antiviral treatment alone’’ would be a cost-effective option at influenza prevalence levels of 2.5% or above, whereas the ‘PCR guided treatment’ approach would be cost-effective at a low prevalence of less than 2.5%.",Not cost-effective,16,decision tree model,68
You (2015),Hong Kong (China),Hospital,Patients hospitalized for suspected active pulmonary TB,Conventional approach; smear plus Xpert (for smear-negative); Xpert,Early treatment; late treatment; both split up in first- and second line (based on whether or not multi-drug resistant),CEA,Decision tree,Healthcare provider's perspective,Both single- and synthesis-based(for different diagnostic strategies),Not stated (appears to be 1 year),economic: 3%; health: NA,Yes,No,$99/QALY,US dollars (2014),"Sensitivity analysis graph (with one parameter varied), CEAC",Using a simple sputum test of Xpert at inital assessment was the most cost-effective option,Cost-effective,12,decision tree model,69
You (2017),China (Hong Kong),Primary care,Elderly patients with ILI,Clinical judgement without testing; rapid molecular POCT,Oseltamivir,CEA,Decision tree,Healthcare provider,Synthesis-based estimates,Lifetime horizon,economic: NA; health: 3%,Yes,No,$29582/QALY,US dollars (2017),"Table of DSA, Tornado diagram of DSA, cost-effectiveness plane, CEAC","The expected ICER of POCT-PCR is SD29,582, lower than 1x GDP per capita of Hong Kong (USD43,497). The base-case ICER is therefore highly cost-effective from the perspective of healthcare provider in Hong Kong.",Cost-effective,15,decision tree model,70
